Upon completion of this program, participants will be able to:
Describe the pathophysiology, natural history, and clinical outcomes related to influenza in the adult population over 65 years.
Describe the estimated burden of disease for adults over 65 years that can be attributed to influenza, and how it varies by demographics, presence of other health conditions, and social determinants.
Summarize biological characteristics of this demographic with respect to the effectiveness and efficacy of influenza vaccines.
Compare different types of influenza vaccines with respect to efficacy, effectiveness, efficiency, and equity (including estimated net benefits, and safety), with a focus on FDA-approved vaccines for use in older adults.
Discuss potential policies/strategies to further protect older adults from influenza, i.e., by improving vaccine uptake in this population, and by immunization of health care providers and other close contacts.
The Influenza Risk Assessment Tool (IRAT) is an evaluation tool being developed by CDC and external influenza experts that seeks to assess the potential pandemic risk posed by influenza A viruses that currently circulate in animals but not in humans.
The most profound consequences of immune senescence with respect to public health are the increased susceptibility to influenza and loss of efficacy of the current split-virus influenza vaccines in older adults, which are otherwise very effective in younger populations. Influenza infection is associated with high rates of complicated illness including pneumonia, heart attacks and strokes in the 65+ population. Changes in both innate and adaptive immune function not only converge in the reduced response to vaccination and protection against influenza, but present significant challenges to new vaccine development. Read More